# A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

> **NCT02075541** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 145 (actual)

## Conditions studied

- Respiratory Disorders

## Interventions

- **BIOLOGICAL:** NTHi-10-AS01E
- **DRUG:** NaCl Placebo

## Key facts

- **NCT ID:** NCT02075541
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-08
- **Primary completion:** 2017-04-19
- **Final completion:** 2017-04-19
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02075541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02075541, "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02075541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*